Cardiff Oncology, Inc. (NASDAQ:CRDF) Stake Increased by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 68.7% during the fourth quarter, HoldingsChannel reports. The fund owned 288,615 shares of the company’s stock after acquiring an additional 117,514 shares during the quarter. Bank of New York Mellon Corp’s holdings in Cardiff Oncology were worth $1,253,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in CRDF. Callan Capital LLC raised its stake in shares of Cardiff Oncology by 11.1% in the 4th quarter. Callan Capital LLC now owns 101,575 shares of the company’s stock valued at $441,000 after purchasing an additional 10,108 shares in the last quarter. Rhumbline Advisers raised its stake in Cardiff Oncology by 24.0% during the fourth quarter. Rhumbline Advisers now owns 53,172 shares of the company’s stock valued at $231,000 after buying an additional 10,290 shares in the last quarter. HB Wealth Management LLC bought a new position in Cardiff Oncology during the 4th quarter worth approximately $105,000. Barclays PLC grew its position in shares of Cardiff Oncology by 291.9% in the 3rd quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after acquiring an additional 39,542 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Cardiff Oncology by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 928,232 shares of the company’s stock valued at $2,479,000 after acquiring an additional 17,557 shares during the last quarter. 16.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CRDF shares. Piper Sandler raised their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. HC Wainwright boosted their price objective on shares of Cardiff Oncology from $13.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, February 28th.

Cardiff Oncology Price Performance

Cardiff Oncology stock opened at $3.75 on Monday. Cardiff Oncology, Inc. has a 12-month low of $2.01 and a 12-month high of $6.42. The stock has a market capitalization of $249.47 million, a PE ratio of -3.99 and a beta of 1.73. The firm has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $3.41.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.